Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Chronic Spontaneous Urticaria
NCT05107115Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of rilzabrutinib in chronic spontaneous urticaria (CSU), sponsored by Sanofi. Started Nov 2021; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05107115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107115.